← Back to Search

Other

Insulin Clamp for Organ Transplant Complications

N/A
Waitlist Available
Led By Dr. Peter Metrakos, MD
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Donors must be over 18 years of age
Be older than 18 years old
Must not have
No solid organs retrieved for transplantation
Diagnosed with Type 1 Diabetes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year post-transplant
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the effects of the glucose/insulin clamp on cadaveric organ donors.

Who is the study for?
This trial is for cadaveric organ donors over 18 years old who have been declared brain dead. It's not for those with uncontrolled high blood sugar, diagnosed with Type 1 Diabetes, or if organs aren't retrieved for transplant. Consent must be obtained under Transplant Quebec regulations.
What is being tested?
The study tests a glucose/insulin clamp technique on deceased donors to prevent high blood sugar and reduce inflammation before organ retrieval. The goal is to improve the survival and function of transplanted hearts, livers, kidneys, and pancreases after one year.
What are the potential side effects?
Since this intervention involves deceased donors rather than living patients, traditional side effects are not applicable in the same way as they would be for interventions given to live subjects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 18 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not donated any organs for transplantation.
Select...
I have been diagnosed with Type 1 Diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year post-transplant
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year post-transplant for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
• Drop in the inflammatory cytokine response after brain death after a minimum of 6 hours therapy with the GICT prior to organ procurement.
Secondary study objectives
Assess organ (heart, liver, pancreas and kidney) survival at one year post-transplant

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Glucose/Insulin ClampExperimental Treatment1 Intervention
Group II: ControlActive Control1 Intervention

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
470 Previous Clinical Trials
166,941 Total Patients Enrolled
Dr. Peter Metrakos, MDPrincipal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre

Media Library

Glucose/Insulin Clamp (Other) Clinical Trial Eligibility Overview. Trial Name: NCT01304290 — N/A
Complication of Organ Transplant Research Study Groups: Control, Glucose/Insulin Clamp
Complication of Organ Transplant Clinical Trial 2023: Glucose/Insulin Clamp Highlights & Side Effects. Trial Name: NCT01304290 — N/A
Glucose/Insulin Clamp (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01304290 — N/A
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top